In a talk in india, NK Cell therapy was mentioned as effective for blood cancers.
Do we have CLL case stories?
vinnet
In a talk in india, NK Cell therapy was mentioned as effective for blood cancers.
Do we have CLL case stories?
vinnet
Did not realize India was more advanced than Germany 🇩🇪!
A couple of articles on CAR NK.
"She concluded that “though CAR-T will revolutionize treatment, autologous T-cell products are expensive and restrictive”. Benefits of CB CAR-NK cells would be that there is no risk of graft-versus-host-disease (GvHD) and more than 100 doses of CAR-NK can be generated from one cord unit thus increasing accessibility and reducing cost. She added that CB is a viable source of off-the-shelf NK cells. According to Professor Rezvani, this therapy may be used in the future as an alternative to T-cells and so far the data has been promising."
targetedonc.com/news/natura...
lymphomahub.com/medical-inf...
Patagozon
Thx for technical reply, bur i am more confused now....
Rgds
vinnet
This may help:
[Dr. Dan Kaufman, the lead scientist in the NK study and director of cell therapy at the UC San Diego School of Medicine, told Healthline that NK cells may offer “significant advantages” over T cells for people with cancer.
This includes the ability to safely deliver these engineered cells in a convenient manner.
Kaufman said that unlike the CAR-T process, the CAR-NK process doesn’t require the cells to be matched to a specific patient.
One batch of iPSC-derived NK cells, which are created in a dish from mature human cells, can be potentially used to treat thousands of people, Kaufman said.
This will enable clinics to offer standardized “off-the-shelf” treatments and use these in combination with other cancer drugs.]
healthline.com/health-news/...
[CAR natural killer (CAR NK) cells could be safer, faster to produce, and cheaper, and they may work in situations where T cells falter.]
mdanderson.org/publications...
Not a treatment as yet. Trial is or has been set up for use of 2 specific Cord Blood Natural Killer Cells and their efficacy in relation to CAR T use weaknesses in treatment.
I have a friend that was in the NK trial, and unfortunately the CLL has returned, so its still quite experimental and some years away from approval I suspect. Certainly bears watching for late stage treatments.
~chris